trending Market Intelligence /marketintelligence/en/news-insights/trending/Jesx5sN-XrRRDs_5xyKVaw2 content esgSubNav
In This List

Neurotrope adds 2 directors

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Neurotrope adds 2 directors

Neurotrope Inc. appointed Ivan Gergel and Jonathan Schechter to its board.

Gergel is the managing partner and chief medical officer of New Rhein Healthcare Investors LLC, while Schechter is director of investment banking at Chardan Capital Markets.

Neurotrope is a biopharmaceutical company focused on developing a product platform for the treatment of Alzheimer's disease.